🍽️ trichlormethiazide,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Hypertension (High Blood Pressure):

    • Trichlormethiazide belongs to the thiazide diuretic class of medications, which work by increasing the excretion of sodium and water from the body through the kidneys.
    • By promoting diuresis (increased urine production), trichlormethiazide helps reduce blood volume and lower blood pressure.
    • It is commonly prescribed as a first-line treatment for essential hypertension and may be used alone or in combination with other antihypertensive drugs to achieve optimal blood pressure control.
  2. Edema (Fluid Retention):

    • Trichlormethiazide is effective in managing edema associated with conditions such as congestive heart failure, liver cirrhosis, renal dysfunction, and certain medications.
    • By increasing urine output and reducing fluid accumulation in tissues, trichlormethiazide helps alleviate symptoms of edema, including swelling, shortness of breath, and fatigue.
  3. Dosage and Administration:

    • Trichlormethiazide is typically administered orally in the form of tablets or capsules.
    • The dosage regimen may vary depending on the patient's age, weight, renal function, and severity of hypertension or edema.
    • It is usually taken once daily in the morning to avoid disrupting sleep patterns.
    • Dosage adjustments may be necessary based on individual patient response and electrolyte balance.
  4. Adverse Effects:

    • Common side effects of trichlormethiazide may include electrolyte imbalances (such as hypokalemia, hyponatremia, and hypomagnesemia), dehydration, dizziness, headache, weakness, gastrointestinal disturbances (nausea, vomiting, diarrhea), and photosensitivity reactions.
    • Rare but serious adverse effects may include allergic reactions, blood dyscrasias (such as leukopenia, thrombocytopenia), hyperglycemia, hyperuricemia (increased uric acid levels), and pancreatitis.
    • Patients should be monitored regularly for signs of electrolyte disturbances, especially during the initial phase of treatment and dosage adjustments.
  5. Contraindications and Precautions:

    • Trichlormethiazide is contraindicated in patients with a known hypersensitivity to sulfonamide-derived medications or any component of the formulation.
    • It should be used with caution in patients with impaired renal function, hepatic impairment, diabetes mellitus, gout, systemic lupus erythematosus (SLE), or electrolyte imbalances.
    • Elderly patients and those with existing electrolyte abnormalities may be at increased risk of adverse effects and require closer monitoring.
  6. Drug Interactions:

    • Trichlormethiazide may interact with other medications, including other diuretics, antihypertensive drugs, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), lithium, and certain antidiabetic agents.
    • Patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking to avoid potential interactions.
;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of trichlormethiazide,(prescription) On Probiotics

Rank Probiotic Impact
genus Bifidobacterium Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Escherichia coli Reduces
species Parabacteroides distasonis Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by trichlormethiazide,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Clostridioides genus Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Enterocloster genus Decreases 👪 Source Study
Odoribacter genus Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Dorea genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Blautia genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
Lachnospira genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Coprococcus genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Segatella genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Escherichia coli O55:H7 no rank Decreases 👶 Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O126:H45 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O145:NM serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O167:H26 serotype Decreases 👶 Source Study
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O6:K2:H1 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Escherichia coli O78:H4 serotype Decreases 👶 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Veillonella parvula species Decreases 📓 Source Study
Bacteroides ovatus species Decreases 📓 Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Lacrimispora saccharolytica species Decreases 📓 Source Study
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Enterocloster bolteae species Decreases 📓 Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Blautia obeum species Decreases 📓 Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Lachnospira eligens species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
Bifidobacterium adolescentis species Decreases 📓 Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Mediterraneibacter gnavus species Decreases 📓 Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Coprococcus comes species Decreases 📓 Source Study
Roseburia hominis species Decreases 📓 Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Roseburia intestinalis species Decreases 📓 Source Study
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Agathobacter rectalis species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of trichlormethiazide,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.1 0.1
Acne 0 0
ADHD 1 0 0
Age-Related Macular Degeneration and Glaucoma 0.2 0 0
Allergic Rhinitis (Hay Fever) 0.7 0.2 2.5
Allergies 1.8 0.2 8
Allergy to milk products 0.7 0.3 1.33
Alopecia (Hair Loss) 0.4 0.4
Alzheimer's disease 1.4 1.4 0
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.7 0.4 0.75
Ankylosing spondylitis 1.4 0.6 1.33
Anorexia Nervosa 0 0.5 0
Antiphospholipid syndrome (APS) 0.6 0.1 5
Asthma 0.1 0.3 -2
Atherosclerosis 0.3 0.4 -0.33
Atrial fibrillation 1 0.7 0.43
Autism 2.9 1.8 0.61
Barrett esophagus cancer 0.5 0.5
benign prostatic hyperplasia 0.2 0.2
Biofilm 0.8 0.8
Bipolar Disorder 0.7 0.4 0.75
Brain Trauma 0.2 0.3 -0.5
Cancer (General) 0.1 0.3 -2
Carcinoma 1.2 0.8 0.5
Celiac Disease 1.1 1.3 -0.18
Cerebral Palsy 0.4 0.4 0
Chronic Fatigue Syndrome 2.3 2 0.15
Chronic Kidney Disease 0.7 0.3 1.33
Chronic Lyme 0.3 -0.3
Chronic Obstructive Pulmonary Disease (COPD) 0.5 0.1 4
Chronic Urticaria (Hives) 1 0 0
Coagulation / Micro clot triggering bacteria 0.7 0.1 6
Colorectal Cancer 1.6 0.2 7
Constipation 0.5 0.1 4
Coronary artery disease 0.2 0.5 -1.5
COVID-19 3.3 2.5 0.32
Crohn's Disease 2.6 1.3 1
cystic fibrosis 0.6 0.3 1
deep vein thrombosis 0.6 0 0
Depression 2 1.6 0.25
Dermatomyositis 0 0
Eczema 0.6 0.1 5
Endometriosis 1.2 0.5 1.4
Eosinophilic Esophagitis 0.2 0.3 -0.5
Epilepsy 0.9 0.4 1.25
Fibromyalgia 0.5 0.5 0
Functional constipation / chronic idiopathic constipation 1.6 0.6 1.67
gallstone disease (gsd) 0.9 0.2 3.5
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.5 0.2 1.5
Generalized anxiety disorder 1 0.5 1
giant cell arteritis 0.1 -0.1
Gout 0 0
Graves' disease 0.5 0.4 0.25
Halitosis 0.7 0.7
Hashimoto's thyroiditis 0.7 0.4 0.75
Hidradenitis Suppurativa 0.3 0.3 0
High Histamine/low DAO 0.7 0 0
hypercholesterolemia (High Cholesterol) 0.2 0.2
hyperglycemia 0.2 0.4 -1
Hyperlipidemia (High Blood Fats) 0.2 0.1 1
hypersomnia 0.2 -0.2
hypertension (High Blood Pressure 0.7 1.1 -0.57
Hypothyroidism 0.2 -0.2
Hypoxia 0.3 0.3
IgA nephropathy (IgAN) 1 -1
Inflammatory Bowel Disease 1.3 1 0.3
Insomnia 0.4 0.4 0
Intelligence 0.1 0 0
Intracranial aneurysms 0.4 0.1 3
Irritable Bowel Syndrome 1.5 1.2 0.25
Liver Cirrhosis 1.7 1 0.7
Long COVID 2.2 2.1 0.05
Low bone mineral density 0.1 -0.1
Lung Cancer 0.2 0.2 0
Mast Cell Issues / mastitis 0.2 0.1 1
ME/CFS with IBS 0.4 0.8 -1
ME/CFS without IBS 0.3 0.8 -1.67
Menopause 0.6 0.6
Metabolic Syndrome 2.2 1.4 0.57
Mood Disorders 3.1 1.6 0.94
multiple chemical sensitivity [MCS] 0.3 0.1 2
Multiple Sclerosis 0.7 0.8 -0.14
Multiple system atrophy (MSA) 0.1 0.1 0
neuropathic pain 0.4 -0.4
Neuropathy (all types) 0.1 0.2 -1
neuropsychiatric disorders (PANDAS, PANS) 0.6 0.6
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.6 1 -0.67
NonCeliac Gluten Sensitivity 0.3 0.3 0
Obesity 2.3 1 1.3
obsessive-compulsive disorder 2.6 1 1.6
Osteoarthritis 0.8 0.8
Osteoporosis 0.8 0.4 1
pancreatic cancer 0.1 0.1
Parkinson's Disease 1.9 1.6 0.19
Polycystic ovary syndrome 0.7 0.3 1.33
Postural orthostatic tachycardia syndrome 0.1 0.1 0
Premenstrual dysphoric disorder 0.3 0 0
primary biliary cholangitis 0.1 0.1 0
Psoriasis 1.4 0.5 1.8
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 1.8 1.3 0.38
Rosacea 0.2 0.1 1
Schizophrenia 1.9 0.3 5.33
scoliosis 0 0.3 0
Sjögren syndrome 1.4 0.7 1
Sleep Apnea 0.3 0.4 -0.33
Slow gastric motility / Gastroparesis 1 0 0
Small Intestinal Bacterial Overgrowth (SIBO) 0.6 0 0
Stress / posttraumatic stress disorder 1.1 0.5 1.2
Systemic Lupus Erythematosus 1.5 0.4 2.75
Tic Disorder 0.1 0.3 -2
Tourette syndrome 0.3 -0.3
Type 1 Diabetes 1.5 0.3 4
Type 2 Diabetes 2.2 1.4 0.57
Ulcerative colitis 1.2 1.2 0
Unhealthy Ageing 2.4 0.3 7

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations / Info / Descriptions are influenced by < a href = "/home/sources" target = "_blank" > Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions / Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [98.81.24 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [98.81.24 ]